GlassScriptPhysician profile
Morteza Tavakol
NPI 1043476807
$121,885.92
in general payments reported to CMS, 2019-2025
44 companies · $1,842 in 2025
The $1,842 reported for 2025 was more than what 82% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55K · 2020: $15K · 2021: $22K · 2022: $12K · 2023: $14K · 2024: $1,765 · 2025: $1,842.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Food and Beverage: $6,061 · Consulting Fee: $1,200 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,302.00 |
| Food and Beverage | $6,061.00 |
| Consulting Fee | $1,200.00 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $48,927.48 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $44,300.74 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14,676.15 | 2019-2025 | Farxiga, Wainua, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $4,470.39 | 2019-2025 | Eliquis, Camzyos |
| Novartis Pharmaceuticals Corporation | $1,968.63 | 2019-2025 | |
| Amgen INC. | $1,426.41 | 2019-2025 | Repatha, Repatha |
| Janssen Pharmaceuticals, INC | $1,238.67 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $536.94 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $480.84 | 2019-2025 | Lux-Dx Insertable Cardiac Monitor, Watchman Flx, Watchman Access System |
| Pfizer INC. | $404.06 | 2019-2025 | |
| Medtronic, INC. | $380.60 | 2021-2024 | Micra, Linq II, Reveal Linq |
| Atricure, INC. | $315.73 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $256.58 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $248.54 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $209.72 | 2019-2022 |
Show all 43 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Morteza Tavakol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.